1734 — Sinphar Pharmaceutical Co Share Price
Last trade - 00:00- TWD5.37bn
- TWD6.47bn
- TWD2.96bn
- 53
- 43
- 40
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.72 | ||
| Price to Tang. Book | 1.76 | ||
| Price to Free Cashflow | 86.41 | ||
| Price to Sales | 1.78 | ||
| EV to EBITDA | 11.67 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.29% | ||
| Return on Equity | 11.94% | ||
| Operating Margin | 10.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 2,394.59 | 2,388.45 | 2,433.52 | 2,856.65 | 2,962.93 | n/a | n/a | 5.98% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +317.21 | n/a | n/a | n/a | +64.97 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sinphar Pharmaceutical Co., Ltd. is principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company is also engaged in the sales of functional food products. The Company’s principal products include ointment, gel, cream, hard and soft capsules, sugar-coated tablets, film-coated tablets, suppositories, powders and granules, lozenges, soft candies, oral and topical liquid medicines, injections, dry medicated powers, functional food products, medical equipment and cosmetics. The Company mainly sells its products to hospitals, drug stores, clinics, dealers and distributors. Its primary markets are located in Taiwan and overseas countries.
Directors
- Chih-Wen Lee CHM
- Yi-Ta Lee VCH
- Zhanglong Chen CEX
- Yunze Lu CEX
- Chao-Re Wang CEX
- Nen-Ying You CEX
- Nen-Yu You CEX
- Yu-Liang Pai GMG
- Fengqin Zhang DGM
- Chih-Hsiao Chen OTH
- Jing-Jing Tang OTH
- Ling-Mo Chao DRC
- Cheng-Che Kuan DRC
- Hsiu-Chih Kuo DRC
- Hongzhi Lin DRC
- Hsiu-Ming Lin DRC
- Nengjun You DRC
- King-Long Lee IND
- Yaoyuan Wen IND
- Xinyu Zou IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- July 2nd, 1977
- Public Since
- October 17th, 2000
- No. of Shareholders
- 57,108
- No. of Employees
- 984
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 167,722,022
- Address
- No.84, DONGSHAN, 269
- Web
- http://www.sinphar.com/
- Phone
- +886 39581101
- Contact
- Chih-Hsiao Chen
- Auditors
- Crowe Horwath (TW) CPAs
Upcoming Events for 1734
Similar to 1734
Adimmune
Taiwan Stock Exchange
Bora Pharmaceuticals Co
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
Chunghwa Chemical Synthesis & Biotech Co
Taiwan Stock Exchange
Formosa Laboratories
Taiwan Stock Exchange
FAQ
As of Today at 23:17 UTC, shares in Sinphar Pharmaceutical Co are trading at TWD32.00. This share price information is delayed by 15 minutes.
Shares in Sinphar Pharmaceutical Co last closed at TWD32.00 and the price had moved by +5.69% over the past 365 days. In terms of relative price strength the Sinphar Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -2.06% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Sinphar Pharmaceutical Co dividend yield is 3.13% based on the trailing twelve month period.
Last year, Sinphar Pharmaceutical Co paid a total dividend of TWD1.00, and it currently has a trailing dividend yield of 3.13%.Looking ahead, the next dividend pay date is 2024-10-08.
We do not have data on when Sinphar Pharmaceutical Co is to next pay dividends. The historic dividend yield on Sinphar Pharmaceutical Co shares is currently 3.13%.
To buy shares in Sinphar Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD32.00, shares in Sinphar Pharmaceutical Co had a market capitalisation of TWD5.37bn.
Here are the trading details for Sinphar Pharmaceutical Co:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 1734
Based on an overall assessment of its quality, value and momentum Sinphar Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinphar Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -3.48%.
As of the last closing price of TWD32.00, shares in Sinphar Pharmaceutical Co were trading -3.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sinphar Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD32.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sinphar Pharmaceutical Co's management team is headed by:
- Chih-Wen Lee - CHM
- Yi-Ta Lee - VCH
- Zhanglong Chen - CEX
- Yunze Lu - CEX
- Chao-Re Wang - CEX
- Nen-Ying You - CEX
- Nen-Yu You - CEX
- Yu-Liang Pai - GMG
- Fengqin Zhang - DGM
- Chih-Hsiao Chen - OTH
- Jing-Jing Tang - OTH
- Ling-Mo Chao - DRC
- Cheng-Che Kuan - DRC
- Hsiu-Chih Kuo - DRC
- Hongzhi Lin - DRC
- Hsiu-Ming Lin - DRC
- Nengjun You - DRC
- King-Long Lee - IND
- Yaoyuan Wen - IND
- Xinyu Zou - IND